The acute pain drug pipeline is experiencing significant advancements, notably with the FDA's January 2025 approval of Journavx (suzetrigine), a first-in-class non-opioid analgesic developed by Vertex Pharmaceuticals. https://blesssocial.com/read-blog/33280